跳至主要内容
临床试验/NCT01869777
NCT01869777已完成不适用

Investigating the Prognostic Importance of Bioelectrical Impedance Phase Angle in Adults Treated for Newly Diagnosed Acute Leukemia

Wake Forest University Health Sciences2 个研究点 分布在 1 个国家目标入组 102 人开始时间: 2013年7月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
102
试验地点
2
主要终点
Treatment Related Mortality Defined as the Percent of Patients no Longer Alive at 60 Days After Registration

研究概览

简要总结

This clinical trial studies bioelectrical impedance measurement for predicting treatment outcome in patients with newly diagnosed acute leukemia. Diagnostic procedures, such as bioelectrical impedance measurement, may help predict a patient's response to treatment for acute leukemia.

详细描述

PRIMARY OBJECTIVES:

I: To determine the feasibility of obtaining standardized phase angle measurements (bioelectrical impedance measurement) on patients hospitalized for treatment of newly diagnosed acute leukemia.

II. To evaluate the association between standardized phase angle measured at the start of therapy and treatment-related outcomes including treatment related mortality (defined as 60-day mortality) III. Evaluate the association of the day 14 standardized phase angle and treatment related outcomes, 30-day mortality, length of hospitalization, transfer to intensive care unit during induction, treatment response (14 day bone marrow response, complete remission), receipt of post-remission therapy, overall survival.

IV. An exploratory analysis investigating associations with the primary and secondary outcomes using different ways to categorize the baseline standardized phase angle and, for acute myeloid leukemia (AML) patients, the standardized phase angle measure obtained just prior to the nadir marrow.

OUTLINE:

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • Hospitalized for newly diagnosed acute leukemia
  • Receiving induction treatment while hospitalized
  • Willing and able to provide written informed consent

排除标准

  • Presence of a pacemaker or defibrillator
  • Patients pregnant at the time of enrollment
  • Any condition or abnormality which may, in the opinion of the investigator, compromise the safety of patients
  • Unable/unwilling to follow protocol requirements

结局指标

主要结局

Treatment Related Mortality Defined as the Percent of Patients no Longer Alive at 60 Days After Registration

时间窗: 60 days

Logistic regression will be used to analyze the association between standardized phase angle and 60 day mortality. 60 day mortality rate is defined as the percent of patients no longer alive at 60 days after registration. Patients that are discharged to hospice care before 60 days without a known date of death will be counted towards 60 day mortality

次要结局

  • Overall Survival(Up to 2 years)
  • Treatment Related Mortality Defined as the Percent of Patients no Longer Alive at 30 Days After Registration(30 days)
  • Length of Hospitalization(Up to 2 years)
  • Number of Participants Transferred to Intensive Care Unit During Induction(Up to 2 years)
  • Number of Participants With Bone Marrow Response(14 days)
  • Number of Participants to Achieve Complete Remission(Up to 2 years)
  • Number of Participants With Receipt of Post-Remission Therapy(Up to 2 years)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Bioelectrical Impedance Measurement for Predicting... | 临床试验